Barron’s analyst Johanna Bennett recommended Perrigo.

Track her picks at:

http://trackthepros.com/

a. IN THE PAST, CASH-STRAPPED CONSUMERS who gladly substituted brand-name household products for cheaper store brands tended to draw the line at their medicine chests. Not anymore.Increasingly, these consumers have been replacing Tylenol, NyQuil and other leading over-the-counter medications with less expensive store-brand alternatives

b. That’s good news for Perrigo, the world’s largest maker of store-brand nonprescription medicines. The company is well positioned to benefit from a slew of new products set to keep pace with rising demand.

c. Profits are set to climb. So despite trading at a price-to-earnings multiple that exceeds that of the broader market, Perrigo’s share price could set a new record in the next 12 months.

d. They dominate the store-brand market, and are the best positioned to take advantage of growing opportunities. Profits, meanwhile, are visible and growing strong. They